semaglutide and gas Use of linked to doubled risk of neovascular macular degeneration Novo Nordisk lowers cost of

GLP-1, GIP and glucagon receptor binding, signalling and downstream pathways

Semaglutide Troche + B6 is a convenient, dissolvable treatment designed to support weight management and metabolic health

GLP-1 receptor agonist drugs protect against diabetic retinopathy, a common complication of diabetes that can lead to sight loss, suggests new research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria (15-19 September) and published in the journal Pharmaceutics.

Research indicates 30-50% of patients regain weight after GLP-1 treatment discontinuation

A clinically positioned GLP-1 metabolic support product provides a credible foundation for building a broader brand ecosystem that may include gut health, muscle preservation, collagen support, energy optimization, and longevity nutrition

Find out if shifting your injection day by 24 hours is medically safe and how to manage your dosing schedule